



Saponin-Based Adjuvants and Immunomodulatory Agent

PI : Prof. Pi-Hui Liang

Department of Pharmacy, National Taiwan University.

Experience:

Associate Professor, Department of Pharmacy, National Taiwan University

<https://scholars.lib.ntu.edu.tw/cris/rp/rp06464>

Market Needs: To develop a safer and more potent human-used vaccines, the addition of immunomodulatory adjuvants to vaccines has dominated today's vaccine formulation. Adjuvant can reduce antigen dose, improve immunoprotection and also reduce the number of administration. In 2017, US FDA approved the first natural-saponin adjuvanted shingle vaccine (Singrix®, GSK). The same saponin adjuvant system has also been applied to malaria vaccine in a phase III clinical trial. In addition, dozens of vaccine interventions with natural saponin adjuvant has been applied in phase I/II clinical trials. Therefore, vaccine manufacturers have a great demand on natural saponin adjuvants; however, natural-derived saponins are limited by its low-yielding purification process and dose limited toxicity. To this end, the synthetic saponin analogues of the present application contains strong cellular immunity enhancing ability, less toxicity and are applicable for mass production.

Our Technology: The synthetic saponin analogues of the present application can induce robust antigen-specific cellular immunity in mice immunization model with lower toxicity. These result indicated that the synthetic saponin analogues of the present application can be applied to prophylactic or therapeutic vaccines.

Strength: The synthetic saponin analogues of the present application contains strong cellular immunity enhancing ability, less toxicity and are applicable for mass production.

Competing Products: Natural-derived saponin adjuvants.

Intellectual Properties:

- (1) Patent pending.
- (2) The research team has over ten years of research experience in the fields of pharmacy, chemistry, cell biology and immunology.

Contact (do not need to fill out):

Center for Industry-Academia Cooperation, NTU

Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw

This information herein is intended for potential license of NTU technology only. Other usage of all or portion of this information in whatever form or means is strictly prohibited. Kindly contact us and we will help to achieve your goal the best we can.